Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Longeveron Inc./ SCHEDULE 13G

SEC Filing · SCHEDULE 13G

Longeveron Inc.

LGVNNASDAQEQUITYCurrent

SEC Filing

Filed Sep 10, 2026Accepted Sep 10, 2026, 4:07 PM EDTCIK 1721484Accession 0000935836-26-000483
View company →Permanent SEC source ↗
Share

Company context

We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®.

Current securities

LGVNNASDAQ · EQUITY · Current
Historical securities (1)
LGVNRNASDAQ · RIGHT · Historical · closed Sep 21, 2023

Recent company filings

  1. Other EventsSep 23, 2026
  2. Other EventsSep 14, 2026
  3. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureAug 24, 2026
  4. 4 filingAug 21, 2026
  5. 4 filingAug 21, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗